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1 5.60  N/A N/A 10 
2  N/A 44.8 10 10 
3 5.60 44.8 N/A 10 
4 1.90 14.9 N/A 10 
5 5.60 44.8 0.25 10 
6 1.90 14.9 0.25 10 
7 5.60 44.8 0.5 10 
8 1.90 14.9 0.5 10 
9 5.60 44.8 1 10 
10 1.90 14.9 1 10 
11 5.60 44.8 2 10 
12 1.90 14.9 2 10 
13 5.60 44.8 4 10 
14 1.90 14.9 4 10 
15 5.60 44.8 8 10 
16 1.90 14.9 8 10 
17 5.60 44.8 16 10 
18 1.90 14.9 16 10 
19 5.60 44.8 32 10 
20 1.90 14.9 32 10 
Figure 2. Anti-Na-GST-1 IgG on Day 14 post prime vaccination.  
Figure 4. Anti-Na-GST-1 IgG on Day 49 post prime vaccination.                                         
(               (Day 14 post boost).  
Figure 5. Fold rise in anti-Na-GST-1 IgG in GMU (Geometric Mean Units)  
Figure 6. Dose Sparing Effect of GLA-AF on D49 post prime vaccination  
                (Day 14 post boost)†.  
Synthetic Glucopyranosyl Lipid Adjuvant (GLA) 
Necator americanus glutathione-S-transferase-1 (Na-GST-1) is a 24-kDa protein 
from  N. americanus that has peroxidase activity and catalyzes the conjugation of 
reduced glutathione to a variety of electrophiles.  Also, Na-GST-1 exhibits a high 
affinity for heme in vitro. Hookworm GSTs may bind and detoxify heme and 
hematin byproducts generated during the blood degradation process. Antibodies 
induced by  Na-GST-1 vaccine will neutralize the activity of Na-GST-1, leading to 
accumulation of heme and hematin. Both heme and hematin contains oxidative 
iron,  which can generate toxic reactive oxygen species that can damage parasite 
structures leading to reduce fecundity and worm burden. The recombinant 
polypeptide Na-GST-1 was expressed in Pichia pastoris. Na-GST-1 Hookworm 
Vaccine Drug Product was formulated at 0.1 mg/ml of Na-GST-1 with 0.8 mg/ml  
of  Alhydrogel® in imidazole, glucose and phosphate buffer. Drug Substance was 
formulated at 2 mg/ml of Na-GST-1.  
Methods  Results Results Results 
The study was comprised of 200 BALB/c Mice (see Table 1 for experimental 
design and dosing information). Ten BALB/c mice per group were immunized 
twice intramuscularly (i.m.) at 5-week intervals with 5.6 µg Na-GST-1/44.8 µg 
Alhydrogel® alone (high dose formulation) or with 5.6 µg Na-GST-1/44.8 µg 
Alhydrogel® mixed with varied doses of GLA-AF. Similarly, Ten Balb/c mice per 
group were immunized twice intramuscularly (i.m.) at 5-week intervals with 1.9 
µg Na-GST-1/14.9 µg Alhydrogel® alone (low dose formulation) or with 1.9 µg 
Na-GST-1/14.9 µg Alhydrogel® mixed with varied doses of GLA-AF. Table 1 
shows the doses and groups in detail. Aeras Manufacturing Record MFG-FM-
257, Lot 09-69D-001 Na-GST-1 Drug Substance was used to generate freshly 
formulated vaccine. 
Table 1. Study Design  
 
Cohort 
 200 Mice  
B1 
V1 
 B3 S 
B= Bleed 
S= Sacrificed 
V= Vaccination (IM) 





Figure 3. Anti-Na-GST-1 IgG on Day 28 post prime vaccination                      
(               
  
Dose used for vaccinating 
animals with GLA-AF 
Anti       
Na-GST-1  
IgG   
(GMU) 
Equivalent vaccine 











5.6 44.8 0.25 6,143 ≈ 7.79 62.95 
5.6 44.8 0.5 7,479 ≈ 9.48 76.63 
5.6 44.8 1 6,115 ≈ 7.75 62.66 
5.6 44.8 2 13,702 ≈ 17.37 140.40 
5.6 44.8 4 13,721 ≈ 17.40 140.59 
5.6 44.8 8 11,250 ≈ 14.27 115.28 
5.6 44.8 16 15,690 ≈ 19.90 160.78 








0.25 = 2.19 18.15 
0.5 = 3.88 31.83 
1 = 2.15 17.86 
2 = 11.77 95.60 
4 = 11.80 95.79 
8 = 8.67 70.48 
16 = 14.30 115.98 
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Mice in the Na-GST-1 high and low dose formulation developed elevated 
levels of IgG to Na-GST-1 after prime and post boost vaccination. Figure 2, 3 
& 4 shows elevated levels of GMU of IgG to Na-GST-1 on D14, D28 and D49 
(D14 post boost) post-prime vaccination in groups receiving 5.6 µg Na-GST-1 
+ 44.8 µg Alhydrogel® (with or without GLA-AF). 
Except for few groups, co-administration of different doses of GLA-AF to a 
high dose of vaccine (5.6 µg Na-GST-1 + 44.8 µg Alhydrogel®) induced a 
statistically significant increase in anti-Na-GST-1 IgG (GMU) on study day 14 
and 28 when compared to anti-Na-GST-1 IgG (GMU) levels in mice 
vaccinated with high dose of vaccine alone (5.6 µg Na-GST-1 + 44.8 µg 
Alhydrogel®) (Figure 2 & 3).   
A boost IgG response was observed in all Na-GST-1 + Alhydrogel groups 
after the second vaccination. Fig 4 shows that Na-GST-1/Alhydrogel co-
administered with GLA-AF (all groups) had statistically significantly elevated 
levels of IgG (GMU) to Na-GST-1 compared to animals receiving only Na-GST-
1 + Alhydrogel on days D49 post-prime (D14 post boost) vaccination for both 
the high and low dose  vaccine groups (Data not shown for the low dose 
groups).  
 Fig 5 shows that the co-administration of 16 µg GLA-AF with the high dose 
Na-GST-1/Alhydrogel® vaccine formulation induced a 9.32 and 12.96 fold rise 
in anti-Na-GST-1 IgG (GMU) on D14 & D28 post prime vaccination 
respectively,  when compared to anti-Na-GST-1 IgG (GMU) in mice 
vaccinated with only the high vaccine dose formulation.  On the contrary, co-
administration of 32 µg GLA-AF induced only 3.29 and 3.67 fold rise in anti-
Na-GST-1 IgG (GMU) on D14 & D28 post prime vaccination respectively. 
A dose dependent, antigen (Na-GST-1) dose sparing effect of GLA-AF was 
observed, when GLA-AF was co-administered with Na-GST-1/Alhydrogel® 
vaccine in BALB/C (Fig 6 & 7).  
More than 740 million people worldwide are infected with Hookworm.  
Hookworm infection is most prevalent in the poorest of the poor populations 
of the world, and has serious health effects. Hookworm infection causes blood 
loss leading to iron deficiency anemia and protein energy malnutrition, which 
results in a compromised immune response. Consequently, the target human 
population suffers from an increased susceptibility to infectious diseases 
including hookworm infection. We have developed recombinant adult 
hookworm vaccines against hookworm infection to break this vicious cycle. 
Necator americanus glutathione-S-transferase-1 (Na-GST-1) is a 24-kDa protein 
from  N. americanus has peroxidase activity and catalyzes the conjugation of 
reduced glutathione to a variety of electrophiles. Recombinant Vaccine 
antigens like Na-GST-1, require adjuvants to enhance the strength and 
duration of the immune response to these antigens which may be weakly 
immunogenic on their own1,2,3. Aluminum salts such as aluminum hydroxide 
and aluminum phosphate (alum) were the only adjuvants in approved human 
vaccines in the USA. Although, alum is effective in boosting antibody 
responses, achieving these responses requires repeated administration. 
Adjuvants like CpGs, MPL, GLA-AF etc  in combination with alum adjuvanted 
vaccines are known to boost immune response in healthy and 
immunocompromised individuals. A non-toxic derivative of LPS, 
monophosphoryl lipid A (MPL) a TLR-4 agonist with alum has been used in two 
vaccines;  the human papilloma virus (Cervarix ®) and hepatitis B virus vaccine 
(Fendrix ®). For Na-GST-1 vaccine, we use a Synthetic Glucopyranosyl Lipid 
Adjuvant- Aqueous Formulation (GLA-AF) which is a pure synthetic 
hexaacylated lipid A derivative when compared to MPL which is naturally-
derived and more heterogenous4,5,6., We believe that co-injecting (GLA-AF) a 
novel TLR-4 agonist with adult hookworm Na-GST-1 + Alhydrogel® vaccine will 
produce a robust and sustainable immune response in this target human 
population. Here, we discuss the study design and the results of the pre-
clinical comparative immunogenicity study of the Human Hookworm Na-GST-1 
+ Alhydrogel® Vaccine in BALB/c mice with and without GLA-AF. 
GLA-AF a pure synthetic hexaacylated lipid A derivative is a novel, clinical-stage, 
human toll-like receptor-4 (TLR-4) agonist8. GLA activates human TLR-4 
receptors, induces Th1 CD4 helper cells and elicits broad humoral immunity. GLA 
was also shown to be safe and well-tolerated in humans subjects in a Phase I 
clinical study in combination with Fluzone® (inactivated influenza virus vaccine)    
Mice were pre-bled, bled on D14 and D28 and Terminal bled on D49 2 weeks 
after the 2nd (boost) immunization. Figure 1. shows the immunization, bleeding 
and sacrifice schedule by study day 
Figure 1. Bleed and Vaccination Schedule   
The levels of IgG against Na-GST-1 was measured in the sera of all BALB/c mice 
by an indirect ELISA and expressed as Arbitrary Units (AU) of IgG Na-GST-1. 
Arbitrary Units were determined by interpolating the OD (492 nm) from test 
serum samples onto a 4 parameter logistic log modeled dose-response curve 
from high titer mice sera. We compared the anti-Na-GST-1-IgG levels between 
the vaccine (Na-GST-1 (µg) and Alhydrogel (µg)) only group and vaccine (Na-
GST-1 (µg) and Alhydrogel (µg)) + GLA-AF group for each bleed. Fold rise in 
anti-Na-GST-1-IgG geometric mean units (GMU) was determine for each 
bleed.  Also, we estimated an approximate amount of Na-GST-1 (µg) and 
Alhydrogel (µg) spared at serially diluted doses of GLA-AF  (µg)  
Figure 7. Dose Sparing Effect of GLA-AF on D49 post prime vaccination  
                (Day 14 post boost)†.  
 
Black Dot (•) represents the anti-Na-GST-1 IgG Units in each mouse.  
p-value estimated using Student’s t-test. 
†Note- BALB/c mice when immunized twice intramuscularly (i.m.) at 5-week 
interval with 5.6 µg Na-GST-1/44.8µg Alhydrogel® (high dose) induced an 1.5 
fold rise in anti-Na-GST-1 IgG (GMU) on Day 49 post prime immunization (D14 
post boost) when compared to anti-Na-GST-1 IgG (GMU) in mice immunized 
with 1.9 µg Na-GST-1/14.9µg Alhydrogel®  (low dose). The above estimates in 
tables 6 & 7 were determine using this fold rise in anti-Na-GST-1 IgG (GMU). 
B= Bleed 
S= Sacrificed 
V= Vaccination (IM) 
